Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
BP Equities (BP Wealth), Canara Bank Securities Ltd, Marwadi Shares and Finance Ltd, Master Capital Services Limited, Nirmal Bang, SMIFS Limited and Ventura Securities Limited have given "Apply" recommendation to Sagility India IPO. Dilip Davda has given "May Apply" recommendation to Sagility India IPO. Capital Market and Swastika Investmart Ltd recommend to "Avoid" the IPO.Axis Capital has "Not Rated" the IPO.
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 7 | 1 | 0 | 2 | 1 |
| % | 63.64 | 9.09 | 0.00 | 18.18 | 9.09 |
| Reviewer | Recommendation | Past Reviews |
|---|---|---|
Axis Capital |
Not Rated |  |
| BP Equities (BP Wealth) |
Apply | |
| Canara Bank Securities Ltd |
Apply | |
| Capital Market |
Avoid | |
| Dilip Davda | May Apply | |
| Marwadi Shares and Finance Ltd |
Apply | |
| Master Capital Services Limited |
Apply | |
| Nirmal Bang |
Apply | |
| SMIFS Limited |
Apply | |
| Swastika Investmart Ltd |
Avoid | |
| Ventura Securities Limited |
Apply | |
The Captial Market (CapitalMarket.com) rating for Sagility India IPO is 38. Their analysis recommends Do not subscribe for the IPO.
| Reviewer | Rating Score | Rating |
|---|---|---|
| Capital Market | 38 | Do not subscribe |
[Dilip Davda] The company specialized health care related technology enabled solutions and services provider to US and other advanced countries. It posted steady growth for FY22 to FY24. Based on annualized FY25, the issue appears aggressively priced. Considering its track records and the future prospects, it is pure long term story. Well-informed/cash surplus investors may park funds for long term. Read detail review...
Sagility India IPO Reviews, analysis and views by popular members. Read Sagility India Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 4 | 1 | 0 | 1 |
| % | 66.67 | 16.67 | 0.00 | 16.67 |
| Member | Review |
|---|---|
| Andy Lomas |
Apply for Long Term at Cut-off Price Great financials
|
| Nambi |
Apply for Listing Gain at Cut-off Price Looking good fundamentals compared to existing IPO's
|
| RamReddy |
Apply for Short Term at Upper Price Band Monopoly business and hard for other companies to enter US healthcare market. Valuation seems high without peers. The large depreciation numbers are intangibles which if taken away, is attractive valuation (EBITDA of 1116 cr FY24 and PAT 228 cr FY24) with good cash flows. Majority of the 600 cr odd Depreciation and amortisation is for intangibles which might result in better PAT in near future. Mature Operations in Philippines which could be lower cost base than India a plus.
|
| Hatchens |
Avoid This is a BPM company serving the healthcare industry. It is just a body shop for customer care and call center operations. There's nothing interesting or groundbreaking in what they do. In the age of AI boom, this is probably the worst type of company in which you can invest your money.
|
| Utkarsh bansal |
Apply for Short Term at Cut-off Price Ipo is priced at attractive valuation and company has good business.
|
| Dhanvantri |
May Apply for Listing Gain at Upper Price Band All Coming ipo retail is 10% which portion going to oversubscribed take chance
|
Post Recommendation Manage Recommendations
Note:
|
| Link|November 4, 2024 8:35:13 PMReply
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
